EA023014B1 - Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции - Google Patents
Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции Download PDFInfo
- Publication number
- EA023014B1 EA023014B1 EA201170911A EA201170911A EA023014B1 EA 023014 B1 EA023014 B1 EA 023014B1 EA 201170911 A EA201170911 A EA 201170911A EA 201170911 A EA201170911 A EA 201170911A EA 023014 B1 EA023014 B1 EA 023014B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ethoxy
- pyridin
- vinyl
- radiopharmaceutical composition
- pet
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 35
- 238000003786 synthesis reaction Methods 0.000 title claims description 31
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title description 26
- 239000002243 precursor Substances 0.000 title description 24
- 239000008194 pharmaceutical composition Substances 0.000 title description 6
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 82
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 82
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 235000010378 sodium ascorbate Nutrition 0.000 claims abstract description 40
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims abstract description 40
- 229960005055 sodium ascorbate Drugs 0.000 claims abstract description 40
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 235000019441 ethanol Nutrition 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 33
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims abstract description 30
- 210000004556 brain Anatomy 0.000 claims abstract description 28
- 238000002600 positron emission tomography Methods 0.000 claims abstract description 24
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 20
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 19
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract description 16
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 16
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 238000003384 imaging method Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 19
- -1 methyl Boc-vinylaniline Chemical compound 0.000 claims description 19
- 206010012289 Dementia Diseases 0.000 claims description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- 208000018737 Parkinson disease Diseases 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 125000006005 fluoroethoxy group Chemical group 0.000 claims description 13
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 7
- MDBUGPWBKWJULZ-CMDGGOBGSA-N 2-[2-[2-[5-[(e)-2-[4-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]phenyl]ethenyl]pyridin-2-yl]oxyethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(N(C(=O)OC(C)(C)C)C)=CC=C1\C=C\C(C=N1)=CC=C1OCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 MDBUGPWBKWJULZ-CMDGGOBGSA-N 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- UKPFKKXSYKZFGA-AATRIKPKSA-N tert-butyl n-[4-[(e)-2-[6-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]phenyl]-n-methylcarbamate Chemical compound C1=CC(N(C(=O)OC(C)(C)C)C)=CC=C1\C=C\C1=CC=C(OCCOCCOCCO)N=C1 UKPFKKXSYKZFGA-AATRIKPKSA-N 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- XDELKSRGBLWMBA-UHFFFAOYSA-N 3-iodopyridine Chemical compound IC1=CC=CN=C1 XDELKSRGBLWMBA-UHFFFAOYSA-N 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 238000002591 computed tomography Methods 0.000 claims description 3
- PZUGJLOCXUNFLM-UHFFFAOYSA-N n-ethenylaniline Chemical compound C=CNC1=CC=CC=C1 PZUGJLOCXUNFLM-UHFFFAOYSA-N 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims 2
- 101100353161 Drosophila melanogaster prel gene Proteins 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- OXHBSDALQBGECT-UHFFFAOYSA-N tert-butyl N-ethenyl-N-phenylcarbamate Chemical compound C(=O)(OC(C)(C)C)N(C1=CC=CC=C1)C=C OXHBSDALQBGECT-UHFFFAOYSA-N 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 235000010323 ascorbic acid Nutrition 0.000 description 11
- 239000011668 ascorbic acid Substances 0.000 description 11
- 230000002285 radioactive effect Effects 0.000 description 11
- 229960005070 ascorbic acid Drugs 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- BIAWAXVRXKIUQB-UHFFFAOYSA-N 2-(2-phenylethenyl)pyridine Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=N1 BIAWAXVRXKIUQB-UHFFFAOYSA-N 0.000 description 8
- 208000037259 Amyloid Plaque Diseases 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- WEQLWGNDNRARGE-DJIMGWMZSA-N (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol Chemical class C1CN2C[C@@H](CC(C)C)[C@H](O)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-DJIMGWMZSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 102000003802 alpha-Synuclein Human genes 0.000 description 5
- 108090000185 alpha-Synuclein Proteins 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003608 radiolysis reaction Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NYCKOPKJAVKWAT-UHFFFAOYSA-N 2-[2-[2-(5-iodopyridin-2-yl)oxyethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOC1=CC=C(I)C=N1 NYCKOPKJAVKWAT-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 206010002022 amyloidosis Diseases 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 210000005064 dopaminergic neuron Anatomy 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- LLKRSJVPTKFSLS-UHFFFAOYSA-N 2-bromo-5-iodopyridine Chemical compound BrC1=CC=C(I)C=N1 LLKRSJVPTKFSLS-UHFFFAOYSA-N 0.000 description 3
- 150000000996 L-ascorbic acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000007070 tosylation reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 230000007082 Aβ accumulation Effects 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 238000007341 Heck reaction Methods 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000005258 radioactive decay Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- MLAYZCMWRNQKQX-UHFFFAOYSA-N 2-hydroxy-1h-isoquinoline Chemical compound C1=CC=C2C=CN(O)CC2=C1 MLAYZCMWRNQKQX-UHFFFAOYSA-N 0.000 description 1
- CCZWSTFVHJPCEM-UHFFFAOYSA-N 2-iodopyridine Chemical compound IC1=CC=CC=N1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010007509 Cardiac amyloidosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000008526 Wells syndrome Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- SCWKRWCUMCMVPW-UHFFFAOYSA-N phenyl n-methylcarbamate Chemical compound CNC(=O)OC1=CC=CC=C1 SCWKRWCUMCMVPW-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical class CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NNEVIHMHALMUSB-UHFFFAOYSA-N tert-butyl n-(4-ethenylphenyl)-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC=C(C=C)C=C1 NNEVIHMHALMUSB-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14188508P | 2008-12-31 | 2008-12-31 | |
| PCT/US2009/069741 WO2010078370A1 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201170911A1 EA201170911A1 (ru) | 2011-12-30 |
| EA023014B1 true EA023014B1 (ru) | 2016-04-29 |
Family
ID=42310197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170911A EA023014B1 (ru) | 2008-12-31 | 2009-12-29 | Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции |
Country Status (35)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010039815A1 (en) * | 2008-09-30 | 2010-04-08 | Case Western Reserve University | Molecular probes for imaging of myelin |
| LT2579902T (lt) | 2010-06-04 | 2017-09-25 | Piramal Imaging Sa | Gamybos būdas amiloido beta ligandų, žymėtų f-18 |
| SG185785A1 (en) | 2010-06-04 | 2013-01-30 | Piramal Imaging Sa | Method for production of f-18 labeled amyloid beta ligand |
| TWI504414B (zh) | 2010-06-04 | 2015-10-21 | Bayer Schering Pharma Ag | 生產Ｆ－１８標記之Ａβ配位體之方法 |
| CN103491870B (zh) * | 2011-04-21 | 2016-12-28 | 加利福尼亚大学董事会 | 官能化磁性纳米颗粒及在淀粉样沉积物和神经原纤维缠结成像中用途 |
| CN105833303A (zh) * | 2011-06-21 | 2016-08-10 | 皮拉莫尔影像股份公司 | 适用于pet成像的氟化茋的制剂 |
| BR112014009013A2 (pt) | 2011-10-19 | 2017-05-02 | Piramal Imaging Sa | método melhorado para a produção de ligandos aß rotulados por f-18 |
| CN102432529B (zh) * | 2011-11-14 | 2014-03-26 | 江苏省原子医学研究所 | 一种苯乙烯基吡啶二硫二氮衍生物的制备方法 |
| JP2015507617A (ja) * | 2011-12-15 | 2015-03-12 | ジーイー・ヘルスケア・リミテッド | タウ病理のイメージングプローブとしての複素環式化合物 |
| CN102526765B (zh) * | 2011-12-31 | 2014-07-30 | 郑州泰基鸿诺药物科技有限公司 | 一种Aβ斑块显像剂及其制备方法 |
| CN103965105A (zh) * | 2013-01-29 | 2014-08-06 | 中山大学 | 苯乙烯基喹啉衍生物及其在治疗阿尔茨海默病症中的应用 |
| CN103645254B (zh) * | 2013-11-28 | 2015-01-07 | 江苏省原子医学研究所 | 一种Aβ斑块显像剂前体AV45的含量分析方法 |
| WO2017014599A1 (ko) * | 2015-07-22 | 2017-01-26 | 주식회사 씨코헬스케어 | [18f]플루오로-도파의 방사화학적 순도를 안정화시키는 조성물 및 이의 제조방법 |
| PL3374358T3 (pl) * | 2015-11-13 | 2021-07-12 | Eli Lilly And Company | Pochodne azetydyny do obrazowania białka tau |
| US10765763B2 (en) | 2016-03-09 | 2020-09-08 | Case Western Reserve University | Radioligands for myelin |
| CN107198780A (zh) * | 2016-03-18 | 2017-09-26 | 南京江原安迪科正电子研究发展有限公司 | 放射性药物组合物及其制备方法、应用 |
| CN106018575B (zh) * | 2016-05-05 | 2018-10-19 | 江苏省原子医学研究所 | 一种PET显像剂前体TsOP-(+)-DTBZ及其光学异构体的分离测定方法 |
| US10695450B2 (en) * | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
| CN109922837A (zh) * | 2016-11-08 | 2019-06-21 | 加利福尼亚大学董事会 | 用于临床应用的[f-18]fddnp的多剂量合成方法 |
| TW201906818A (zh) * | 2017-05-31 | 2019-02-16 | 美商５１１製藥公司 | 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用 |
| BR112020014594A8 (pt) * | 2018-01-24 | 2022-12-13 | Ac Immune Sa | Composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico |
| CN111499544B (zh) * | 2019-01-31 | 2022-12-02 | 中国医学科学院放射医学研究所 | 一种一锅法制备N-Boc-N-甲基-4-氨基苯乙烯的合成方法 |
| CN111499570B (zh) * | 2019-01-31 | 2023-05-16 | 中国医学科学院放射医学研究所 | 一种av-45中间体的合成方法 |
| US20220175973A1 (en) * | 2019-03-29 | 2022-06-09 | National Institutes for Quantum Science and Technology | Method for producing radiopharmaceutical and radiopharmaceutical |
| CN115403434A (zh) * | 2021-05-26 | 2022-11-29 | 汉中汉核医疗科技有限公司 | 一种放射性药物的合成方法 |
| CN115400232A (zh) * | 2021-05-26 | 2022-11-29 | 汉中汉核医疗科技有限公司 | 一种放射性药物合成方法 |
| CN113582885B (zh) * | 2021-08-30 | 2023-04-21 | 南京克米斯璀新能源科技有限公司 | 一种烷基磺酸钠的生产方法 |
| CN114805190A (zh) * | 2022-06-08 | 2022-07-29 | 吉林大学第一医院 | 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法 |
| CN120187703A (zh) * | 2022-11-14 | 2025-06-20 | 伊莱利利公司 | 氟贝他吡前体av-105的多晶型物 |
| CN119080714A (zh) * | 2024-09-12 | 2024-12-06 | 四川大学 | 一种偶氮苯磺酸酯化合物及其制备方法和应用、放射性探针的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070281299A1 (en) * | 2004-01-19 | 2007-12-06 | Youdim Moussa B | Diagnostic Test For Parkinson's Disease |
| US20080038195A1 (en) * | 2006-03-30 | 2008-02-14 | The Trustees Of The University Of Pennsylvania | Stryrylpyridine derivates and theur use for binding and imaging amylod plaques |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA012334B1 (ru) * | 2004-12-17 | 2009-08-28 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Производные стильбена и их применение для связывания и визуализации амилоидных бляшек |
-
2009
- 2009-12-29 SG SG2011048055A patent/SG172439A1/en unknown
- 2009-12-29 AU AU2009335049A patent/AU2009335049B2/en active Active
- 2009-12-29 EP EP09837135.4A patent/EP2381967B1/en active Active
- 2009-12-29 MY MYPI2011003056A patent/MY162312A/en unknown
- 2009-12-29 MX MX2011007063A patent/MX2011007063A/es active IP Right Grant
- 2009-12-29 HR HRP20170453TT patent/HRP20170453T1/hr unknown
- 2009-12-29 US US12/648,869 patent/US20100172836A1/en not_active Abandoned
- 2009-12-29 JP JP2011543721A patent/JP5717650B2/ja active Active
- 2009-12-29 UA UAA201109307A patent/UA105914C2/uk unknown
- 2009-12-29 PT PT98371354T patent/PT2381967T/pt unknown
- 2009-12-29 CA CA2748705A patent/CA2748705C/en active Active
- 2009-12-29 EA EA201170911A patent/EA023014B1/ru not_active IP Right Cessation
- 2009-12-29 PE PE2011001294A patent/PE20120007A1/es not_active Application Discontinuation
- 2009-12-29 NZ NZ593848A patent/NZ593848A/xx unknown
- 2009-12-29 DK DK09837135.4T patent/DK2381967T3/en active
- 2009-12-29 CN CN200980153414.5A patent/CN102271716B/zh active Active
- 2009-12-29 MA MA34065A patent/MA33004B1/fr unknown
- 2009-12-29 ES ES09837135.4T patent/ES2620402T3/es active Active
- 2009-12-29 SI SI200931600A patent/SI2381967T1/sl unknown
- 2009-12-29 HU HUE09837135A patent/HUE033649T2/en unknown
- 2009-12-29 BR BRPI0923890-5A patent/BRPI0923890A2/pt active Search and Examination
- 2009-12-29 WO PCT/US2009/069741 patent/WO2010078370A1/en not_active Ceased
- 2009-12-29 LT LTEP09837135.4T patent/LT2381967T/lt unknown
- 2009-12-29 PL PL09837135T patent/PL2381967T3/pl unknown
- 2009-12-29 RS RS20170117A patent/RS55674B1/sr unknown
- 2009-12-29 KR KR1020117017636A patent/KR20110119670A/ko not_active Ceased
-
2011
- 2011-06-20 IL IL213674A patent/IL213674A/en active IP Right Grant
- 2011-06-24 TN TN2011000318A patent/TN2011000318A1/fr unknown
- 2011-06-29 ZA ZA2011/04824A patent/ZA201104824B/en unknown
- 2011-06-29 HN HN2011001810A patent/HN2011001810A/es unknown
- 2011-06-29 DO DO2011000210A patent/DOP2011000210A/es unknown
- 2011-07-11 CO CO11086470A patent/CO6341578A2/es active IP Right Grant
- 2011-07-29 EC EC2011011242A patent/ECSP11011242A/es unknown
- 2011-07-29 CR CR20110410A patent/CR20110410A/es unknown
-
2017
- 2017-02-24 CY CY20171100253T patent/CY1118658T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070281299A1 (en) * | 2004-01-19 | 2007-12-06 | Youdim Moussa B | Diagnostic Test For Parkinson's Disease |
| US20080038195A1 (en) * | 2006-03-30 | 2008-02-14 | The Trustees Of The University Of Pennsylvania | Stryrylpyridine derivates and theur use for binding and imaging amylod plaques |
Non-Patent Citations (2)
| Title |
|---|
| SOUZA et al. Longitudinal noninvasive PET-based Beta cell mass estimates in a spontanecus diabetes rat model. Journal of Clinical Investigation, June 2006, Vol. 116, pp. 1508-1513; pg. 1508, col. 2, para 1 * |
| ZHANQ et al. F-18 Stilbenes as PET imaging Agents for Detecting Beta-Amyloid Plaques in the Brain. Journal of Medicinal Chemistry, 2006, Vol. 48, pp. 5880-5988; pg. 5982, Scheme 4; col. 1, para 1 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023014B1 (ru) | Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции | |
| TWI528977B (zh) | New amyloid affinity products | |
| US9040021B2 (en) | Heterocyclic compounds as imaging probes of tau pathology | |
| AU2014338155B2 (en) | Tau imaging probe | |
| Nan et al. | 6-Methoxy-indanone derivatives as potential probes for β-amyloid plaques in Alzheimer's disease | |
| US20210038747A1 (en) | Novel method of preparing an imaging compound | |
| US9211350B2 (en) | Compound with amyloid affinity | |
| JP2007223952A (ja) | アミロイドβ蛋白が蓄積する疾患の画像診断プローブ | |
| JPWO2009057576A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
| Yang et al. | Preliminary evaluation of fluoro-pegylated benzyloxybenzenes for quantification of β-amyloid plaques by positron emission tomography | |
| JP2013237655A (ja) | コンフォメーション病診断用分子プローブ | |
| JPWO2014132919A1 (ja) | 診断用組成物 | |
| US20220227728A1 (en) | Microtubule-associated protein Tau imaging compounds for Alzheimer's disease and precursors thereof | |
| HK1162951B (en) | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof | |
| JP7284490B2 (ja) | モノアミンオキシダーゼｂイメージングプローブ | |
| WO2025091145A1 (zh) | 糖尿病肾病诊断药物及应用 | |
| JP2021102593A (ja) | タウを画像化する新規化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |